Understanding The Potential of EIF3A as A Drug Target (G8661)

Target Name: EIF3A

NCBI ID: G8661

EIF3A

Understanding The Potential of EIF3A as A Drug Target

EIF3A, also known as eIF3A-p170, is a protein that is expressed in various tissues and cells in the human body. Its function in the cell is still not well understood, but research has shown that it plays a role in a variety of cellular processes, including cell signaling, DNA replication, and metabolism.

One of the most promising aspects of EIF3A is its potential as a drug target. Its unique structure and subcellular localization have led to the idea that it may be a good target for small molecules that can modulate its activity and potentially lead to therapeutic benefits.

EIF3A is a protein that is composed of 254 amino acids. It is expressed in various tissues and cells in the human body, including the brain, heart, liver, and muscle. Its function in the cell is not well understood, but research has shown that it plays a role in a variety of cellular processes.

One of the most promising aspects of EIF3A is its potential as a drug target. Its unique structure and subcellular localization have led to the idea that it may be a good target for small molecules that can modulate its activity and potentially lead to therapeutic benefits.

EIF3A has been shown to play a role in a variety of cellular processes, including cell signaling, DNA replication, and metabolism. For example, studies have shown that EIF3A is involved in the regulation of the DNA replication process, which is important for the development and maintenance of new cells.

In addition, EIF3A has also been shown to be involved in cell signaling. It has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is important for the development and maintenance of tissues and organs, and alterations in its activity have been linked to a variety of diseases, including cancer.

EIF3A's subcellular localization also suggests that it may be a good target for small molecules that can modulate its activity. Since EIF3A is primarily expressed in the cytoplasm of the cell, it is possible that small molecules that can be targeted to the cytoplasm may be able to modulate its activity. This is an exciting area of research, as there are a wide variety of potential small molecules that could potentially be used to modulate EIF3A's activity.

In conclusion, EIF3A is a protein that is expressed in various tissues and cells in the human body. Its unique structure and subcellular localization have led to the idea that it may be a good target for small molecules that can modulate its activity. Further research is needed to fully understand its function and potential as a drug target.

Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit A

Functions: RNA-binding component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632, PubMed:11169732). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773, PubMed:27462815)

The "EIF3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets